AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. Expands Disinfectant Effectiveness/Qualification Services in St. Louis, MO
WILMINGTON, North Carolina, Sept. 29, 2015 /PRNewswire/ -- AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. (AAI/CML) has recently expanded its service capabilities to offer two sites as options for placement of Disinfectant Effectiveness/ Disinfectant Qualification (DE/DQ) studies. In order to meet a high customer demand, provide regional support and complement the existing services from the Edison, NJ, facility, AAI/CML now offers DE/DQ at its St. Louis, MO facility. These studies satisfy the requirements of USP <1072> Disinfectants and Antiseptics and support clients with their needs to comply with cGMP 21 CFR 211.67, Equipment Cleaning and Maintenance.
Logo - http://photos.prnewswire.com/prnh/20150806/256637LOGO
The expansion allows AAI/CML to further support sterile and non-sterile product manufacturers in the development and qualification of disinfectant programs to prevent microbial contamination through pharmaceutical ingredients, process water, packaging components, manufacturing environment, process and manufacturing equipment.
"We are excited to expand our disinfectant qualification systems to our St. Louis facility and provide the kind of robust systems needed to prevent microbial contamination in the manufacture of pharmaceutical products," stated Ted Dolan, Chief Operating Officer. "This added capability allows us to offer more options for regional proximity and flexibility for manufacturing and testing with AAI/CML from both our St. Louis, MO and Edison, NJ sites."
About AAIPharma Services Corp. and Cambridge Major Laboratories, Inc.
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With seven sites across the globe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services. The family of companies is in the portfolio of American Capital, Ltd. (NASDAQ: ACAS). Contact us for all your drug development and manufacturing needs at www.aaipharma.com and www.c-mlabs.com.
Share this article